| Original language | English (US) |
|---|---|
| Pages (from-to) | 1698-1705 |
| Number of pages | 8 |
| Journal | American Journal of Cardiology |
| Volume | 99 |
| Issue number | 12 |
| DOIs |
|
| State | Published - Jun 15 2007 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The Editor's Roundtable : High-Density Lipoprotein Cholesterol. / Friedewald, Vincent E.; Brewer, H. Brian; Grundy, Scott M; Rader, Daniel J.; Roberts, William C.
In: American Journal of Cardiology, Vol. 99, No. 12, 15.06.2007, p. 1698-1705.Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - The Editor's Roundtable
T2 - High-Density Lipoprotein Cholesterol
AU - Friedewald, Vincent E.
AU - Brewer, H. Brian
AU - Grundy, Scott M
AU - Rader, Daniel J.
AU - Roberts, William C.
N1 - Funding Information: This activity is supported by an educational grant from Pfizer, Inc. New York, New York. Funding Information: Dr. Friedewald has no relevant financial relationship to disclose. Dr. Brewer has received fees for consulting from Merck, White House Station, New Jersey; Merck/Schering Plough, North Wales, Pennsylvania; Lipid Sciences, Pleasanton, California; Pfizer, Inc., New York, New York; Novartis, East Hanover, New Jersey; sanofi-aventis, Bridgewater, New Jersey. Dr. Grundy has received research grants from Merck, White House Station, New Jersey; Abbott, Abbott Park, Illinois; KOS Pharmaceuticals, Weston, Florida; and has worked as a Consultant for Merck; Merck/Schering Plough, Kenilworth, New Jersey; KOS Pharmaceuticals; Pfizer, Inc., New York, NY; Eli Lilly, Indianapolis, Indiana; GlaxoSmithKline, Research Triangle Park, North Carolina; Abbott; Fournier, Montreal, Quebec, Canada; Bristol-Myers Squibb, Plainsboro, New Jersey; Sankyo, Parsippany, New Jersey; AstraZeneca, Wilmington, Delaware; and sanofi-aventis, Bridgewater, New Jersey. Dr. Rader has received fees for speakers bureau from AstraZeneca, Wilmington, Delaware; Merck, White House Station, New Jersey; Merck/Schering Plough, North Wales, Pennsylvania; Pfizer, Inc., New York, New York; has worked on the Advisory Committees for AstraZeneca; Boehringer Ingelheim, Ridgefield, Connecticut; Bristol Myers Squibb, Plainsboro, New Jersey; KOS Pharmaceuticals, Weston, Florida; Merck; Merck/Schering Plough, North Wales, Pennsylvania; Pfizer; Schering-Plough, Kenilworth, New Jersey; and has worked as a Consultant for AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; KOS Pharmaceuticals; Merck; Merck/Schering Plough; Pfizer, Inc.; and Schering-Plough. Dr. Rader has also received Grant/Research Support from AstraZeneca, Wilmington, Delaware; Boehringer Ingelheim, Ridgefield, Connecticut; Bristol Myers Squibb, Plainsboro, New Jersey; Bruin Pharma, Los Angeles, California; GlaxoSmithKline, Research Triangle Park, North Carolina; KOS Pharmaceuticals, Weston, Florida; Merck and Co., White House Station, New York; and Pfizer, New York, New York. Dr. Rader has received no honoraria, other than those listed above. Dr. Roberts has received honoraria for speaking from Merck, North Wales, Pennsylvania; Schering Plough, Kenilworth, New Jersey; Pfizer, Inc., New York, NY; AstraZeneca, Wilmington, Delaware; and Novartis, East Hanover, New Jersey. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2007/6/15
Y1 - 2007/6/15
UR - http://www.scopus.com/inward/record.url?scp=34250003487&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250003487&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2007.03.020
DO - 10.1016/j.amjcard.2007.03.020
M3 - Comment/debate
C2 - 17560878
AN - SCOPUS:34250003487
VL - 99
SP - 1698
EP - 1705
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 12
ER -